|
|
||
 |
|||
|
|||
DOI: 10.1369/jhc.3A6195.2004
Volume 52 (7): 893-901, 2004
Copyright ©The Histochemical Society, Inc.
Immunohistochemical Detection of EGFR in Paraffin-embedded Tumor Tissues : Variation in Staining Intensity Due to Choice of Fixative and Storage Time of Tissue Sections
University Witten/Herdecke, Institute of Pathology, Wuppertal, Germany (DA,SS); Merck KGaA, Darmstadt, Germany (K-AR); DakoCytomation A/S, Glostrup, Denmark (CLT,HW); and University of Applied Sciences, Münster, Germany (MSB)
Correspondence to: Prof. Dr. Med. S. Störkel, Inst. of Pathology, University Witten/Herdecke, Helios-Klinikum, Wuppertal, Heusnerstr.40, 42283 Wuppertal, Germany. E-mail: sstoerkel{at}wuppertal.helios-kliniken.de
The epidermal growth factor receptor (EGFR) is highly expressed in a variety of solid malignant tumors and its expression has been correlated with disease progression and poor survival. With the advent of targeted therapies, especially IMC-C225 (Cetuximab), a monoclonal antibody (MAb) directed against the EGFR, there is an increasing interest in immunohistochemistry (IHC)-based EGFR screening methods using paraffin-embedded tumor specimens to select cancer patients eligible for treatment with Cetuximab. With the EGFRpharmDX kit, a complete assay for demonstration of EGFR is now available. Because no information about the preservation of the EGFR under various conditions of fixation is available, we performed a prospective study on a panel of commonly used fixatives to determine optimal tissue preservation protocols. The stability of the epitope on cut tissue sections stored for a period up to 24 month was also tested using material originating from patients with head and neck cancer, non-small-cell lung carcinomas, and colorectal adenocarcinomas. Depending on the fixative used and the time of storage of cut tissue sections, a variation in the determined level of EGFR expression was demonstrated compared with the most optimal fixation procedure. (J Histochem Cytochem 52:893–901, 2004)
Key Words: immunohistochemistry • tissue preservation • fixation protocols • EGFR • stored slides
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
|
|
 |
|
  F. Loupakis, C. Cremolini, G. Fontanini, I. Stasi, L. Salvatore, and A. Falcone Review: Beyond KRAS: perspectives on new potential markers of intrinsic and acquired resistance to epidermal growth factor receptor inhibitors in metastatic colorectal cancer Therapeutic Advances in Medical Oncology, November 1, 2009; 1(3): 167 - 181. [Abstract] [PDF]
|
|
|
|
 |
|
 H Adams, A Tzankov, A Lugli, and I Zlobec New time-dependent approach to analyse the prognostic significance of immunohistochemical biomarkers in colon cancer and diffuse large B-cell lymphoma J. Clin. Pathol., November 1, 2009; 62(11): 986 - 997. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. W. Stewart, E. E.W. Cohen, L. Licitra, C. M.L. Van Herpen, C. Khorprasert, D. Soulieres, P. Vodvarka, D. Rischin, A. M. Garin, F. R. Hirsch, et al. Phase III Study of Gefitinib Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck J. Clin. Oncol., April 10, 2009; 27(11): 1864 - 1871. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V Martin, L Mazzucchelli, and M Frattini An overview of the epidermal growth factor receptor fluorescence in situ hybridisation challenge in tumour pathology J. Clin. Pathol., April 1, 2009; 62(4): 314 - 324. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Mutsaers, G. Francia, S. Man, C. R. Lee, J. M.L. Ebos, Y. Wu, L. Witte, S. Berry, M. Moore, and R. S. Kerbel Dose-Dependent Increases in Circulating TGF-{alpha} and Other EGFR Ligands Act As Pharmacodynamic Markers for Optimal Biological Dosing of Cetuximab and Are Tumor Independent Clin. Cancer Res., April 1, 2009; 15(7): 2397 - 2405. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Burns, Y. Li, C. A. Cheney, Y. Ou, L. L. Franlin-Pfeifer, N. Kuklin, and Z.-Q. Zhang Choice of Fixative Is Crucial to Successful Immunohistochemical Detection of Phosphoproteins in Paraffin-embedded Tumor Tissues J. Histochem. Cytochem., March 1, 2009; 57(3): 257 - 264. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Schittenhelm, C. Kollmannsberger, K. Oechsle, A. Harlow, J. Morich, F. Honecker, R. Kurek, S. Storkel, L. Kanz, C. L. Corless, et al. Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancer Mol. Cancer Ther., March 1, 2009; 8(3): 481 - 489. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. A. Fisher, T. Kuo, M. Ramsey, E. Schwartz, R. V. Rouse, C. D. Cho, J. Halsey, and B. I. Sikic A Phase II Study of Gefitinib, 5-Fluorouracil, Leucovorin, and Oxaliplatin in Previously Untreated Patients with Metastatic Colorectal Cancer Clin. Cancer Res., November 1, 2008; 14(21): 7074 - 7079. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I Zlobec, L Terracciano, L Tornillo, U Gunthert, T Vuong, J R Jass, and A Lugli Role of RHAMM within the hierarchy of well-established prognostic factors in colorectal cancer Gut, October 1, 2008; 57(10): 1413 - 1419. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Personeni, S. Fieuws, H. Piessevaux, G. De Hertogh, J. De Schutter, B. Biesmans, W. De Roock, A. Capoen, M. Debiec-Rychter, J.-L. Van Laethem, et al. Clinical Usefulness of EGFR Gene Copy Number as a Predictive Marker in Colorectal Cancer Patients Treated with Cetuximab: A Fluorescent In situ Hybridization Study Clin. Cancer Res., September 15, 2008; 14(18): 5869 - 5876. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I Zlobec and A Lugli Prognostic and predictive factors in colorectal cancer Postgrad. Med. J., August 1, 2008; 84(994): 403 - 411. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I Zlobec and A Lugli Prognostic and predictive factors in colorectal cancer J. Clin. Pathol., May 1, 2008; 61(5): 561 - 569. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Yamada, Y. Ichikawa, S. Yamagishi, N. Momiyama, M. Ota, S. Fujii, K. Tanaka, S. Togo, S. Ohki, and H. Shimada Amphiregulin Is a Promising Prognostic Marker for Liver Metastases of Colorectal Cancer Clin. Cancer Res., April 15, 2008; 14(8): 2351 - 2356. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Graziano, A. Ruzzo, F. Loupakis, E. Canestrari, D. Santini, V. Catalano, R. Bisonni, U. Torresi, I. Floriani, G. Schiavon, et al. Pharmacogenetic Profiling for Cetuximab Plus Irinotecan Therapy in Patients With Refractory Advanced Colorectal Cancer J. Clin. Oncol., March 20, 2008; 26(9): 1427 - 1434. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Eberhard, G. Giaccone, and B. E. Johnson Biomarkers of Response to Epidermal Growth Factor Receptor Inhibitors in Non-Small-Cell Lung Cancer Working Group: Standardization for Use in the Clinical Trial Setting J. Clin. Oncol., February 20, 2008; 26(6): 983 - 994. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Zlobec, R. Steele, L. Terracciano, J. R Jass, and A. Lugli Selecting immunohistochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer J. Clin. Pathol., October 1, 2007; 60(10): 1112 - 1116. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L Taillade, F Penault-Llorca, T Boulet, P Fouret, S Michiels, E Taranchon, G Mountzios, P Validire, J Domont, P Girard, et al. Immunohistochemichal expression of biomarkers: a comparative study between diagnostic bronchial biopsies and surgical specimens of non-small-cell lung cancer Ann. Onc., June 1, 2007; 18(6): 1043 - 1050. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Su, M. J. Shrubsole, R. M. Ness, Q. Cai, N. Kataoka, K. Washington, and W. Zheng Immunohistochemical Expressions of Ki-67, Cyclin D1, {beta}-Catenin, Cyclooxygenase-2, and Epidermal Growth Factor Receptor in Human Colorectal Adenoma: A Validation Study of Tissue Microarrays. Cancer Epidemiol. Biomarkers Prev., September 1, 2006; 15(9): 1719 - 1726. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Italiano, F. B. Vandenbos, J. Otto, J. Mouroux, D. Fontaine, P.-Y. Marcy, N. Cardot, A. Thyss, and F. Pedeutour Comparison of the epidermal growth factor receptor gene and protein in primary non-small-cell-lung cancer and metastatic sites: implications for treatment with EGFR-inhibitors Ann. Onc., June 1, 2006; 17(6): 981 - 985. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Romeo, J. Wunderlich, L. Ngo, S. A. Rosenberg, S. M. Steinberg, and D. M. Berman Measuring Tissue-Based Biomarkers by Immunochromatography Coupled with Reverse-Phase Lysate Microarray Clin. Cancer Res., April 15, 2006; 12(8): 2463 - 2467. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kong, P. Leboucher, R. Leek, V. Calleja, S. Winter, A. Harris, P. J. Parker, and B. Larijani Prognostic value of an activation state marker for epidermal growth factor receptor in tissue microarrays of head and neck cancer. Cancer Res., March 1, 2006; 66(5): 2834 - 2843. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H Nakamura, N Kawasaki, M Taguchi, and K Kabasawa Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis Thorax, February 1, 2006; 61(2): 140 - 145. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A Frieze and J. S McCune Current Status of Cetuximab for the Treatment of Patients with Solid Tumors Ann. Pharmacother., February 1, 2006; 40(2): 241 - 250. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. K. Bergsland When Does the Presence of the Target Predict Response to the Targeted Agent? J. Clin. Oncol., January 10, 2006; 24(2): 213 - 216. [Full Text] [PDF]
|
|
|
|
|
|
H Awaya, Y Takeshima, O Furonaka, N Kohno, and K Inai Gene amplification and protein expression of EGFR and HER2 by chromogenic in situ hybridisation and immunohistochemistry in atypical adenomatous hyperplasia and adenocarcinoma of the lung J. Clin. Pathol., October 1, 2005; 58(10): 1076 - 1080. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Italiano, M.-C. Saint-Paul, F.-X. Caroli-Bosc, E. Francois, A. Bourgeon, D. Benchimol, J. Gugenheim, and J.-F. Michiels Epidermal growth factor receptor (EGFR) status in primary colorectal tumors correlates with EGFR expression in related metastatic sites: biological and clinical implications Ann. Onc., September 1, 2005; 16(9): 1503 - 1507. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. Dicker and U. Rodeck Predicting the Future From Trials of the Past: Epidermal Growth Factor Receptor Expression and Outcome of Fractionated Radiation Therapy Trials J. Clin. Oncol., August 20, 2005; 23(24): 5437 - 5439. [Full Text] [PDF]
|
|
|
|
|
|
N. J. Meropol Epidermal Growth Factor Receptor Inhibitors in Colorectal Cancer: It's Time to Get Back on Target J. Clin. Oncol., March 20, 2005; 23(9): 1791 - 1793. [Full Text] [PDF]
|
|
|
|
|
|
K. Y. Chung, J. Shia, N. E. Kemeny, M. Shah, G. K. Schwartz, A. Tse, A. Hamilton, D. Pan, D. Schrag, L. Schwartz, et al. Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry J. Clin. Oncol., March 20, 2005; 23(9): 1803 - 1810. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Saltz In Reply: J. Clin. Oncol., February 1, 2005; 23(4): 923 - 924. [Full Text] [PDF]
|
|
|
|
 |
|
 L.C. AMLER, A.D. GODDARD, and K.J. HILLAN Predicting Clinical Benefit in Non-Small-Cell Lung Cancer Patients Treated with Epidermal Growth Factor Tyrosine Kinase Inhibitors Cold Spring Harb Symp Quant Biol, January 1, 2005; 70(0): 483 - 488. [Abstract] [PDF]
|
|
| Guidelines | Subscriptions | About | exPRESS - Current - Archive | Business Information | Contact |
